ArticleJournal of virology2026
Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Within-host SARS-CoV-2 diversity during acute infection is largely characterized by low-frequency intra-host single-nucleotide variants (iSNVs), but whether early iSNV patterns differ by immune status remains unclear. We analyzed biobanked diagnostic specimens from adults with RT-qPCR-confirmed SARS-CoV-2 infection collected in Cali, Colombia, between 2020 and 2022. Immunocompromised cases sampled during the acute phase were classified into four clinical categories, and immunocompetent cases from the same catchment area were used for comparison. Whole-genome sequencing (Illumina) yielded 102 high-quality genomes (≥85% coverage; immunocompetent, IMPORTANCE: Understanding how immune status shapes within-host SARS-CoV-2 diversity is key for interpreting transmission risk and evolutionary potential. Immunocompromised patients are often presumed to harbor more diverse viral populations, yet evidence early in infection remains limited. Analyzing samples, we compared minor variant (intra-host single-nucleotide variant [iSNV]) patterns between immunocompromised and immunocompetent individuals and evaluated lineage-specific effects. We found comparable within-host diversity, but normalized polymorphic sites were higher in immunocompetent than in immunocompromised individuals when considering all lineages. We observed an Mµ-restricted S-region signal: immunocompetent hosts showed higher S-region iSNV allele frequencies, whereas immunocompromised hosts exhibited a shift toward synonymous S-region iSNVs. These results refine assumptions about early infection in immunocompromised hosts, emphasize the value of reporting synonymous and non-synonymous changes, and highlight that conclusions can depend on viral lineage and the diversity metric considered. Our study underscores the need for immunophenotype-informed studies to test whether synonymous iSNVs modulate viral expression, replication, and transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.